US FDA approves Gilead's twice-yearly injection for HIV prevention
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Gilead Sciences (GILD) Yeztugo approval a 'major win' - BMO Capital
June 18, 2025 3:21 PM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $120.00 price target on Gilead Sciences (NASDAQ: GILD) after the company announced the FDA has approved Yeztugo (lenacapavir)the companys injectable HIV-1 capsid inhibitoras pre-exposure prophylaxis (PrEP) to reduce the risk of... More
